Cell line · CVCL_0337
Papers47
1 to 20 of 47
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Hyperactive PLCG1 induces cell-autonomous and bystander T cell activation and drug resistance. | EMBO Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. | Exp Dermatol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IL-9 Promotes Migratory Dissemination of Malignant T Cells by Activating the HIF-1α-Cofilin-1 Axis in Cutaneous T-cell Lymphoma. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Encapsulation and Delivery of the Kinase Inhibitor PIK-75 by Organic Core High-Density Lipoprotein-Like Nanoparticles Targeting Scavenger Receptor Class B Type 1. | ACS Appl Mater Interfaces | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Development and Evaluation of a TaqMan Real-Time PCR Assay for the Rapid Detection of Cross-Contamination of RD (Human) and L20B (Mouse) Cell Lines Used in Poliovirus Surveillance. | J Virol Methods | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma. | EBioMedicine | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells. | J Hematol Oncol | 2019 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0337/papers